Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study by van den Elsen, SHJ et al.
1van den Elsen SHJ, et al. BMJ Open 2020;10:e035350. doi:10.1136/bmjopen-2019-035350
Open access 
Prospective evaluation of improving 
fluoroquinolone exposure using 
centralised therapeutic drug monitoring 
(TDM) in patients with tuberculosis 
(PERFECT): a study protocol of a 
prospective multicentre cohort study
Simone HJ van den Elsen,1 Marieke GG Sturkenboom,1 Onno Akkerman,2,3 
Linda Barkane,4 Judith Bruchfeld,5,6 Geoffrey Eather,7 Scott K Heysell,8 
Henadz Hurevich,9 Liga Kuksa,4 Heinke Kunst,10 Johanna Kuhlin,5,6 
Katerina Manika,11 Charalampos Moschos,12 Stellah G Mpagama,13 
Marcela Muñoz Torrico,14 Alena Skrahina,9 Giovanni Sotgiu,15 Marina Tadolini,16 
Simon Tiberi,17 Francesca Volpato,16 Tjip S van der Werf,2,18 Malcolm R Wilson,7 
Joaquin Zúñiga,19,20 Daan J Touw,1 Giovanni B Migliori,21 
Jan- Willem Alffenaar   1,22To cite: van den Elsen SHJ, 
Sturkenboom MGG, 
Akkerman O, et al.  Prospective 
evaluation of improving 
fluoroquinolone exposure 
using centralised therapeutic 
drug monitoring (TDM) in 
patients with tuberculosis 
(PERFECT): a study protocol 
of a prospective multicentre 
cohort study. BMJ Open 
2020;10:e035350. doi:10.1136/
bmjopen-2019-035350
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
035350).
DJT, GBM and J- WA contributed 
equally.
Received 29 October 2019
Revised 06 March 2020
Accepted 21 May 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Jan- Willem Alffenaar;  
 j. w. c. alffenaar@ umcg. nl
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Global multidrug- resistant tuberculosis 
(MDR- TB) treatment success rates remain suboptimal. 
Highly active WHO group A drugs moxifloxacin and 
levofloxacin show intraindividual and interindividual 
pharmacokinetic variability which can cause low drug 
exposure. Therefore, therapeutic drug monitoring (TDM) 
of fluoroquinolones is recommended to personalise 
the drug dosage, aiming to prevent the development of 
drug resistance and optimise treatment. However, TDM 
is considered laborious and expensive, and the clinical 
benefit in MDR- TB has not been extensively studied. This 
observational multicentre study aims to determine the 
feasibility of centralised TDM and to investigate the impact 
of fluoroquinolone TDM on sputum conversion rates in 
patients with MDR- TB compared with historical controls.
Methods and analysis Patients aged 18 years or older 
with sputum smear and culture- positive pulmonary MDR- 
TB will be eligible for inclusion. Patients receiving TDM 
using a limited sampling strategy (t=0 and t=5 hours) 
will be matched to historical controls without TDM in 
a 1:2 ratio. Sample analysis and dosing advice will 
be performed in a centralised laboratory. Centralised 
TDM will be considered feasible if >80% of the dosing 
recommendations are returned within 7 days after 
sampling and 100% within 14 days. The number of 
patients who are sputum smear and culture- negative 
after 2 months of treatment will be determined in the 
prospective TDM group and will be compared with the 
control group without TDM to determine the impact of 
TDM.
Ethics and dissemination Ethical clearance was 
obtained by the ethical review committees of the 10 
participating hospitals according to local procedures or 
is pending (online supplementary file 1). Patients will be 
included after obtaining written informed consent. We aim 
to publish the study results in a peer- reviewed journal.
trial registration number  ClinicalTrials. gov Registry 
(NCT03409315).
IntroduCtIon
Tuberculosis (TB) is one of the major infec-
tious diseases worldwide with an estimated 
number of 10 million new cases in 2017.1 In 
addition, multidrug- resistant TB (MDR- TB) 
strengths and limitations of this study
 ► To our knowledge, this is the first study that investi-
gates the impact of fluoroquinolone therapeutic drug 
monitoring (TDM) on sputum smear and culture con-
version rates in prospective patients with multidrug- 
resistant tuberculosis (MDR- TB) versus historical 
controls without TDM.
 ► The feasibility for centralised TDM will be evaluated 
due to the participation of multiple healthcare cen-
tres located in differently- resourced countries from 
multiple regions in the world.
 ► The use of limited sampling strategies will reduce 
the burden of TDM for patients and healthcare pro-
viders while still providing a reliable estimation of 
drug exposure.
 ► A limitation is that this study focuses on TDM for 
moxifloxacin and levofloxacin only, being core drugs 
in MDR- TB treatment, without assessing other (core) 
anti- TB drugs.
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remains a persistent problem with an estimated 458 000 
new patients in 2017.1 MDR- TB is treated from 9 to 20 
months with a multidrug regimen.2 The grouping of 
second- line anti- TB drugs was revised in 2018 by the 
WHO.3 The fluoroquinolones, specifically moxiflox-
acin and levofloxacin, are now considered drugs of first 
choice (group A drugs), together with bedaquiline and 
linezolid, in the treatment of MDR- TB.2 3 The adminis-
tration of group A medicines to patients with MDR- TB 
has been associated with increased treatment success and 
reduced mortality rates in comparison with other second- 
line anti- TB drugs.4 However, the estimated prevalence of 
fluoroquinolone resistance among MDR- TB cases is on 
the rise from 14.5% in 2011 to 22% in 2017.5 6 Misman-
agement of MDR- TB treatment, especially the shorter 
regimen, could amplify the risk of drug resistance even 
further.7 Importantly, antibiotic resistance can be acquired 
due to non- compliance but also insufficient drug expo-
sures (eg, interindividual pharmacokinetic variability in 
patients treated with fluoroquinolones).8–11 Therapeutic 
drug monitoring (TDM) can help to prevent acquired 
resistance by individualising doses based on blood drug 
concentrations relative to the bacterial susceptibility, 
ideally measured as the minimal inhibitory concentration 
(MIC).7 12
Several studies described the role played by low drug 
concentrations on treatment outcomes.13–15 In the light 
of this evidence, it can be hypothesised that TDM, which 
aims for adequate dosing and exposure, could improve 
treatment outcomes. Yet, the added value of TDM in 
MDR- TB treatment outcomes has not been directly 
studied.16 17 One retrospective study reported the effect 
of TDM on the treatment results of patients with drug- 
susceptible TB, either with and without diabetes.18 In 
the group without diabetes, TDM had a significant 
beneficial effect with 73% sputum culture conversion at 
2 months among patients receiving TDM versus 60% in 
the control group. The positive effect of TDM was even 
larger in patients with diabetes and TB. The isoniazid or 
rifampicin dose was adjusted in 12 out of 17 (71%) of 
the patients with diabetes based on peak concentration 
(Cmax) targets. However, this data is not available for the 
group without diabetes. To the best of our knowledge, 
such controlled studies have not yet been performed in 
people with MDR- TB.
The pharmacokinetic- pharmacodynamic param-
eter of fluoroquinolones is both time- dependent and 
concentration- dependent and therefore uses the ratio 
of area under the concentration–time curve (AUC) to 
MIC (AUC0–24/MIC). The target value is AUC0–24/MIC 
>146 for levofloxacin and free or unbound fAUC0–24/
MIC >53 for moxifloxacin which corresponds to a total 
(bound and unbound) AUC0–24/MIC >106 assuming a 
constant protein binding of 50%.19 20 However, multiple 
concentration measurements widely distributed over 
the dosing interval are required to compute the AUC 
from 0 to 24 hours (AUC0–24). Limited sampling strate-
gies (LSSs) could be adopted to reduce the burden of 
frequent sampling for both patient and personnel while 
providing a reliable estimation of AUC0–24 using only two 
blood samples.21 22
Unfortunately, TDM is not always easily accessible in 
high- TB- burden areas because of practical and financial 
reasons. Therefore, centralised TDM could be a valuable 
service.23 Large laboratories are generally well organised, 
have highly trained personnel with the adequate perfor-
mance of analytical methods leading to reliable sample 
analysis results.24 In addition, centralising the TDM 
procedures will engender more consistent practice from 
healthcare practitioners familiar with TDM and the provi-
sion of dosing advice for anti- TB drugs.
The aim of the present study is: first, to investigate the 
feasibility of centralised TDM of moxifloxacin and levo-
floxacin in the treatment of MDR- TB recruited in TB 
reference centres located in different continents. Second, 
the impact of TDM on treatment results will be assessed 
by comparing 2 month sputum smear and culture conver-
sion rates among patients who received TDM compared 
with matched historical controls without TDM.
MEthods And AnAlysIs
study design
This observational, prospective, multicentre study aims to 
evaluate the feasibility of centralised TDM of moxiflox-
acin and levofloxacin as well as the impact of TDM on 
2 month sputum smear and culture conversion rates of 
patients with MDR- TB. Study design and procedures are 
displayed in figure 1. The study was registered at  clinical-
trials. gov, recruitment started on 10 February 2018, and is 
expected to be completed in December 2020.
study location
University Medical Center Groningen (UMCG) in Gron-
ingen, The Netherlands, is the coordinating centre and 
serves as the central laboratory facility for this study. The 
hospitals that are involved in patient recruitment are 
displayed in table 1.
study population
Patients aged 18 years and older are eligible for inclu-
sion if they are diagnosed with pulmonary MDR- TB, have 
positive sputum smear and culture samples at the time 
of inclusion, are treated with either oral moxifloxacin 
or levofloxacin, and provide written informed consent. 
Pregnant or breastfeeding women will be excluded. The 
decision whether a patient is treated with either moxiflox-
acin or levofloxacin is made by the clinician at the start of 
TB treatment based on local guidelines. Patients will not 
be actively assigned to use moxifloxacin or levofloxacin 
since this is an observational study.
A total number of 120 patients (60 with moxifloxacin 
and 60 with levofloxacin) will be prospectively included 
and compared with 240 matched historical controls (120 
with moxifloxacin and 120 with levofloxacin).
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Figure 1 Workflow of study procedures in local hospitals 
and central laboratory facility. MDR- TB, multidrug- resistant 
tuberculosis; TDM, therapeutic drug monitoring.
Table 1 List of participating hospitals and their location
Hospital Location
University Medical Center 
Groningen (Central Lab Facility)
Groningen, The 
Netherlands
Tuberculosis Clinic “Beatrixoord”, 
UMCG
Haren, The Netherlands
Princess Alexandra Hospital Brisbane, Australia
Karolinska University Hospital Stockholm, Sweden
Instituto Nacional de 
Enfermedades Respiratorias
Mexico City, Mexico
Athens Chest Hospital “Sotiria” Athens, Greece
Kibong’oto Infectious Diseases 
Hospital
Kilimanjaro, Tanzania
Republican Scientific and 
Practical Centre for Pulmonology 
and Tuberculosis
Minsk, Belarus
Barts Health NHS Trust London, UK
St. Orsola- Malpighi Hospital, 
University of Bologna
Bologna, Italy
Riga East University Hospital TB 
and Lung Disease Clinic
Riga, Latvia
NHS, National Health Service; TB, tuberculosis; UMCG, University 
Medical Center Groningen.
The following data will be collected in both groups: 
sex, age, body weight, height, country of birth, country 
of residence, comorbidities, QTc interval, laboratory 
values (kidney and liver function, electrolytes), history of 
previous TB treatment, bacterial susceptibility (including 
MIC if available), TB presentation (cavitary or non- 
cavitary), current MDR- TB regimen (including drug 
dosages), sputum smear and culture data, treatment 
outcome (if known) and details on fluoroquinolone use 
(duration, possible drug interactions or adverse events).
Historical control patients will be matched on age, sex, 
Mycobacterium tuberculosis resistance pattern of the isolate 
(only regimen core drugs), comorbidities (HIV, diabetes 
and immunosuppression), presence or absence of cavi-
tary TB on chest radiography and dosing of the fluoro-
quinolone (mg/kg body weight, ±10%) to prospectively 
enroled patients in a 2:1 ratio.
Interventions
The objective of the feasibility of centralised TDM will 
be assessed by evaluating the process, by which a locally 
collected sample will be analysed in a central labora-
tory and subsequent dosing advice will be returned to 
the local physician. In brief, after at least 7 days of treat-
ment (steady state), two blood samples will be collected 
for TDM of moxifloxacin or levofloxacin according to 
a previously developed LSS.21 22 The first sample will be 
collected just before drug intake (t=0) and the other at 
5 hours after drug intake (t=5). Samples will be trans-
ported to the central laboratory for drug analysis and will 
be accompanied by a form including key patient char-
acteristics for personalised dosing advice (ie, sex, age, 
weight, height, serum creatinine, QTc interval, MIC, TB 
presentation, start of treatment, other anti- TB drugs and 
comorbidities). AUC0–24 will be calculated using a popula-
tion pharmacokinetic model21 22 and Bayesian dose opti-
misation in MWPharm++ (V.1.7.3; Mediware, Groningen, 
The Netherlands).
Dosing is optimised based on AUC0–24/MIC or AUC0–
24 (in case MIC is unknown), taking into consideration 
comorbidities (HIV, diabetes and immunosuppression), 
the persistence of TB symptoms and response to treat-
ment so far. The Bayesian dosing software uses sex, age, 
height, weight and renal function in addition to drug dose 
and measured drug concentrations to forecast the drug 
exposure after a dose change. For patients who are at risk 
for treatment failure due to the previously mentioned 
reasons, a higher drug exposure is recommended. This is 
especially relevant in the case of an unknown individual 
MIC since the actual MIC might be near the breakpoint, 
to prevent treatment failure and acquired resistance. The 
target AUC0–24/MIC and AUC0–24 are shown in table 1. If 
a dose change is necessary, TDM is to be repeated after 
at least 7 days after the initiation of the new dose (steady 
state). Dose increases of moxifloxacin will not be advised 
in the case of a prolonged QTc interval (>450 ms for men 
and >470 ms for women) because of safety reasons. As 
levofloxacin may be less cardiotoxic than moxifloxacin, 
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Table 2 Target AUC0–24/MIC and AUC0–24 for TDM of moxifloxacin and levofloxacin in patients with MDR- TB
Fluoroquinolone Pulmonary MDR- TB
Target AUC0–24/MIC*
Target AUC0–24 (mg*h/L)MGIT 7H10/11 LJ
Moxifloxacin Standard disease >100 >50 >25 >40
Severe disease or comorbidities >100 >50 >25 >60†
Levofloxacin Standard disease >150 >150‡ >75 >150
Severe disease or comorbidities >150 >150‡ >75 >200†
Standard disease is defined as non- cavitary and regular disease on the radiograph. Severe disease is defined as cavitary or extensive disease 
on the radiograph.
*MIC varies depending on growth media; mycobacteria growth indicator tubes (MGIT), Middlebrook 7H10/7H11, and Lowenstein- Jensen (LJ) 
agar.
†Target AUC0–24/MIC at site of cavity; therefore, higher AUC0–24 is required.
‡Levofloxacin critical concentration of 7H11 was extrapolated to 7H10.
AUC 
, area under the concentration–time curve; LJ, Lowenstein- Jensen; MDR- TB, multidrug- resistant tuberculosis; MGIT, mycobacteria growth 
indicator tubes; MIC, minimal inhibitory concentration; TDM, therapeutic drug monitoring.
levofloxacin dose increases are permitted in the case of 
prolonged QTc interval, but only with adequate electro-
cardiogram monitoring. Patients with prolonged QTc 
interval will not be excluded from the study since TDM 
can still be helpful to verify drug exposure. A closely 
monitored follow- up including MIC determination can 
be advised in the case of AUC0–24 of 25– 40 mg*h/L in 
combination with QTc interval prolongation. In the case 
of very low moxifloxacin exposure (AUC0–24<20 mg*h/L) 
in combination with a prolonged QTc interval, the physi-
cian will be advised to reconsider the anti- TB regimen as 
moxifloxacin may be less active than expected.
laboratory methods
Drug analysis
Measurement of moxifloxacin and levofloxacin plasma/
serum concentrations will take place at the laboratory of 
the Department of Clinical Pharmacy and Pharmacology 
in the UMCG, The Netherlands, and using validated 
liquid chromatography- mass spectrometry methods. The 
method for levofloxacin has an accuracy of 0.1%–12.7%, 
within- run precision of 1.4%–2.4% and between- run 
precision of 3.6%–4.1%. The calibration curve is linear 
over a range of 0.10–5.00 mg/L.25 This range was success-
fully expanded to 0.20–50.0 mg/L in a recent update of 
the method (data on file). Accuracy of the moxifloxacin 
method is 2.7%–7.1%, within- run precision 1.4%–1.6% 
and between- run precision 1.0%–1.6%. The calibration 
curve is linear over a range of 0.05–5.00 mg/L.26 For both 
fluoroquinolones, only the total concentration (bound 
and unbound) will be measured. Therefore, the target 
AUC0–24/MIC values of >150
19 and >10020 will be used for 
levofloxacin and moxifloxacin, respectively (table 2).
Plasma and serum samples containing levofloxacin are 
stable for at least 10 days at 50°C and can, therefore, be 
transported to the central facility in ambient temperature, 
without the need of transport on dry ice.27 The thermal 
stability of moxifloxacin was also tested according to the 
method of Ghimire et al and showed that moxifloxacin 
serum and plasma samples are stable for at least 10 days 
at 50°C as well (data on file).
Microbiology
The assessment of sputum smear and culture status 
after 2 months of MDR- TB treatment will be performed 
according to the local procedures, but at least once a 
month until documented culture conversion. MIC deter-
mination is preferred but not mandatory for TDM and 
will be performed according to local procedures as well. 
To account for the differences in culture media used in 
drug susceptibility testing, correction factors based on the 
critical concentrations in the WHO document ‘Technical 
Report on critical concentrations for drug susceptibility 
testing of medicines used in the treatment of drug- 
resistant tuberculosis’ will be applied.28 The target AUC0–
24/MIC values for each medium are shown in table 2. 
Furthermore, second- line molecular drug susceptibility 
tests will be considered in case MIC data are not available.
data analysis plan
The primary outcome to assess the feasibility of centralised 
TDM will be the turn- around time, which is defined by 
the time between blood sampling and the peripheral 
centres receiving the TDM results including the dosing 
advice. The procedure is considered feasible if >80% of 
the collected samples will be reported back to the physi-
cian within 7 days and 100% within 2 weeks. Additionally, 
the feasibility will be evaluated using secondary outcomes 
of sample quality after shipping and completeness of 
required information on the sample form.
Furthermore, we will evaluate the role of TDM on 
MDR- TB treatment by comparing the percentages of 
patients with sputum smear and culture conversion at 
2 months in the enrolled groups. In addition, we will eval-
uate the number of patients with low fluoroquinolone 
exposure requiring dose changes after TDM to estimate 
the potential gains.
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sample size calculation
As the primary endpoint was of descriptive nature and 
no data were available to perform a well- informed sample 
size calculation, it was decided to power the study on the 
clinical impact of TDM. The primary assumption was 
based on the detection of a proportional difference in 
sputum smear and culture positivity at 2 months of treat-
ment in patients with MDR- TB undergoing TDM (35%)29 
and control patients (60%).30 Given an alpha error of 
0.05 and statistical power of 80%, we calculated a sample 
size of 60 per single group (ie, 60 prospective and 120 
historical control patients for moxifloxacin and equally 
for levofloxacin).
PAtIEnt And PublIC InvolvEMEnt
There has been no patient or public involvement in the 
design of this study.
EthICs And dIssEMInAtIon
This study will be performed according to the Declara-
tion of Helsinki and Good Clinical Practice.31 In each 
recruiting centre, ethical clearance has been granted 
according to local regulations and patient recruitment has 
begun at most sites (online supplementary file 1). Written 
informed consent will be obtained from all patients 
undergoing TDM. The need of new informed consent 
for historical controls was waived because of the use of 
retrospective anonymous data collected for program-
matic purposes or previously reported data from studies 
for which patients had provided informed consent.
This study includes historical patients who did 
not receive TDM as controls instead of prospectively 
randomising patients to either receive or not receive 
TDM for ethical reasons. The evidence that TDM actu-
ally improves MDR- TB treatment outcomes has not 
been confirmed in randomised controlled trials, but 
multiple studies have described treatment failure and 
risk of antibiotic resistance due to subtherapeutic drug 
exposure of anti- TB drugs.8 13 15 19 20 In combination with 
a large between- patient pharmacokinetic variability,9 10 
we hypothesise that TDM is able to improve treatment 
outcomes by ensuring adequate exposure in individual 
patients. Moreover, TDM for MDR- TB is recommended 
in guidelines when it is available.2 32 33 We, therefore, 
considered it unethical to withhold TDM.
Study results will be published in a peer- reviewed journal 
and will be presented at an international conference.
dIsCussIon
We present an observational prospective multicentre study 
which aims to: (a) evaluate the feasibility of centralised 
TDM in differently resourced settings of varying TB ende-
micity and geographic region and (b) evaluate the role of 
TDM of moxifloxacin or levofloxacin on sputum smear 
and culture conversion rates in patients with MDR- TB 
after 2 months of treatment.
Presently, TDM is offered as an adjunctive to patients 
with TB in only a few hospitals worldwide and is considered 
to be part of the excellent clinical care.16 23 34–36 However, 
general interest in TDM and MDR- TB treatment optimis-
ation has been increasing. A consensus statement on the 
diagnosis and treatment of MDR- TB in Europe states that 
TDM for second- line drugs should be used if available.33 
Moreover, the use of second- line anti- TB drugs was listed 
in the American Thoracic Society guidelines as an indica-
tion for TDM and TDM is also recommended in the Euro-
pean Union Standards for Tuberculosis Prevention and 
Care.32 37 Yet, TDM is considered by some to be laborious, 
expensive and thus unpractical in countries with high TB 
incidence. Similar injurious arguments of economistic 
rationing of services were applied to second- line drugs 
for the treatment of MDR- TB in highly endemic settings 
and such rationing conversely led to amplification of the 
MDR- TB epidemic.38 This study will focus on the feasibility 
of centralised TDM, which could stimulate performing 
TDM more often as it requires only one qualified labo-
ratory with validated analytical methods and devices in 
a central location. Other options to facilitate TDM are 
the implementation of LSSs, urine samples, dried- blood 
spots and saliva- screening methods.34 39–41 This study will 
additionally use LSSs to increase feasibility as well as to 
reduce the burden of TDM. The LSSs for moxifloxacin 
and levofloxacin used in this study (0 and 5- hour post-
dose samples) were designed to optimise AUC0–24,
21 22 
whereas the frequently used sampling schedule at 2- hour 
and 6- hour postdose is more suitable to estimate Cmax and 
identify delayed absorption.42
Although incorporating TDM in TB treatment has 
shown to give high treatment success rates in low endemic 
countries, such as The Netherlands,29 this has not yet 
been evaluated in well- designed randomised controlled 
trials.43 This study will provide a first- ever conclusion on 
the value of TDM of moxifloxacin and levofloxacin on 
sputum smear and culture conversion of patients with 
MDR- TB.
It can be considered a limitation that only TDM of 
fluoroquinolones is performed in this study. However, 
moxifloxacin and levofloxacin are currently among the 
core drugs in the MDR- treatment regimen together with 
linezolid and bedaquiline.3 Based on TDM criteria,44 we 
have selected moxifloxacin and levofloxacin because they 
show large interindividual pharmacokinetic variability, 
which emphasises the need for personalised dosing.9 10 
Moreover, fluoroquinolone resistance is on the rise and 
can develop during low drug exposure.8 TDM of fluoro-
quinolones aims to find the individual patients who have 
low drug exposure and would benefit from dose adjust-
ment. Therefore, it is expected that the TDM of fluo-
roquinolones will have the largest impact on MDR- TB 
treatment outcomes. We did not include TDM for 
linezolid and bedaquiline in this study because of unclear 
evidence for TDM of bedaquiline due to the novelty of 
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the drug45 and TDM of linezolid has focused more on 
preventing toxicity.46–48
Another limitation is that we are only evaluating interim 
outcomes such as sputum conversion rates at 2 months 
and will not assess outcomes at the end of treatment. 
However, this study is primarily designed to determine the 
feasibility of centralised TDM. In addition, this is the first 
study to evaluate the impact of fluoroquinolone TDM. 
We believe that reporting the results on sputum conver-
sion rates is relevant as bacterial load and risk of acquired 
resistance are highest in the first months of therapy. Fast 
sputum culture conversion reduces the risk of transmis-
sion of M. tuberculosis strains which continues to sustain 
the MDR- TB epidemic.49 With the results of this study, we 
aim to design a future study to extensively evaluate TDM 
of all drugs in the regimen including the final treatment 
outcomes. However, such study would require substantial 
funding.
We hope that this study will show that centralised 
TDM is feasible and that TDM can improve the quality 
of treatment in terms of faster sputum conversion rates 
compared with historical experience. If that might be the 
case, the major hesitations about TDM in TB treatment 
can be attenuated favouring the improvement of TB 
management using a personalised approach.37
Author affiliations
1Department of Clinical Pharmacy and Pharmacology, University of Groningen, 
University Medical Center Groningen, Groningen, The Netherlands
2Department of Pulmonary Diseases and Tuberculosis, University of Groningen, 
University Medical Center Groningen, Groningen, The Netherlands
3Tuberculosis Center Beatrixoord, University of Groningen, University Medical Center 
Groningen, Haren, The Netherlands
4Department of Multidrug Resistant Tuberculosis, Riga East University Hospital TB 
and Lung Disease Clinic, Riga, Latvia
5Division of Infectious Diseases, Department of Medicine, Solna, Karolinska 
Institutet, Stockholm, Sweden
6Department of Infectious Diseases, Karolinska University Hospital, Stockholm, 
Sweden
7Department of Respiratory Medicine and Metro South Clinical Tuberculosis Service, 
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
8Division of Infectious Diseases and International Health, University of Virginia, 
Charlottesville, Virginia, USA
9The Republican Scientific and Practical Center for Pulmonology and Tuberculosis, 
Minsk, Belarus
10Department of Respiratory Medicine, Blizard Institute, Queen Mary University of 
London, Barts Health NHS Trust, London, UK
11Pulmonary Department, Respiratory Infections Unit, G. Papanikolaou Hospital, 
Aristotle University of Thessaloniki, Thessaloniki, Greece
12Drug- Resistant Tuberculosis Unit, 'Sotiria' Hospital for Chest Diseases, Athens, 
Greece
13Kibong'oto Infectious Diseases Hospital, Kilimanjaro, United Republic of Tanzania
14Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, Mexico 
City, Mexico
15Department of Medical, Surgical and Experimental Sciences, Clinical Epidemiology 
and Medical Statistics Unit, University of Sassari, Sassari, Italy
16Department of Medical and Surgical Sciences, Unit of Infectious Diseases, Alma 
Mater Studiorum University of Bologna, Bologna, Italy
17Department of Infection, Blizard Institute, Queen Mary University of London, Barts 
Health NHS Trust, London, UK
18Department of Internal Medicine, University of Groningen, University Medical 
Center Groningen, Groningen, The Netherlands
19Laboratory of Immunobiology and Genetics, Instituto Nacional de Enfermedades 
Respiratorias, Mexico City, Mexico
20Tecnologico de Monterrey, Escuela de Medicina y Ciencias de Salud, Mexico City, 
Mexico
21Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici 
Scientifici Maugeri IRCCS, Tradate, Italy
22Sydney Pharmacy School, Faculty of Medicine and Health, The University of 
Sydney, Sydney, New South Wales, Australia
Acknowledgements The project is part of the scientific activities of the 
Global Tuberculosis Network (GTN; Committees on Pharmacology: chair J- WA; 
Treatment: chair MMT and Global TB Consilium: chairs MT and ST) and of the 
WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 
2017–2020- GBM/RC/LDA.
Contributors SHJvdE, MGGS, DJT, GBM and J- WA designed the major outlines of 
the study. OA, LB, JB, GE, SKH, HH, LK, HK, JK, KM, CM, SGM, MMT, AS, GS, MT, ST, 
FV, TSvdW, MRW and JZ contributed to the study design. OA, LB, JB, GE, SKH, HH, 
LK, HK, JK, KM, CM, SGM, MMT, AS, MT, ST, FV, TSvdW, MRW and JZ will include 
patients in the study. GS performed the sample size calculation. SHJvdE wrote the 
first draft of the manuscript together with MGS, DJT, and J- WA. All authors read and 
approved the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in 
the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId id
Jan- Willem Alffenaar http:// orcid. org/ 0000- 0001- 6703- 0288
rEFErEnCEs
 1 World Health Organization. Global tuberculosis report, 2018.
 2 World Health Organization. WHO consolidated guidelines on drug- 
resistant tuberculosis treatment, 2019.
 3 World Health Organization. Rapid communication: key changes to 
treatment of multidrug- and rifampicin- resistant tuberculosis (MDR/
RR- TB), 2018.
 4 Collaborative Group for the Meta- Analysis of Individual Patient Data 
in MDR- TB treatment–2017, Ahmad N, Ahuja SD, et al. Treatment 
correlates of successful outcomes in pulmonary multidrug- resistant 
tuberculosis: an individual patient data meta- analysis. Lancet 
2018;392:821–34.
 5 Alffenaar J- WC, Migliori GB, Gumbo T. Multidrug- resistant 
tuberculosis: pharmacokinetic and pharmacodynamic science. 
Lancet Infect Dis 2017;17:898.
 6 World Health Organization. Global tuberculosis report, 2012.
 7 Davies Forsman L, Bruchfeld J, Alffenaar J- WC. Therapeutic drug 
monitoring to prevent acquired drug resistance of fluoroquinolones in 
the treatment of tuberculosis. Eur Respir J 2017;49:1700173.
 8 Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug- resistant 
tuberculosis not due to noncompliance but to between- patient 
pharmacokinetic variability. J Infect Dis 2011;204:1951–9.
 9 Van't Boveneind- Vrubleuskaya N, Seuruk T, van Hateren K, et al. 
Pharmacokinetics of levofloxacin in multidrug- and extensively 
drug- resistant tuberculosis patients. Antimicrob Agents Chemother 
2017;61:e00343–17.
 10 Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of 
moxifloxacin for the treatment of tuberculosis: 3 years of experience. 
Eur Respir J 2011;38:888–94.
 11 Ghimire S, Van't Boveneind- Vrubleuskaya N, Akkerman OW, 
et al. Pharmacokinetic/pharmacodynamic- based optimization of 
levofloxacin administration in the treatment of MDR- TB. J Antimicrob 
Chemother 2016;71:2691–703.
 12 Alffenaar J- WC, Gumbo T, Aarnoutse RE. Acquired drug resistance: 
we can do more than we think! Clin Infect Dis 2015;60:969–70.
 o
n
 June 23, 2020 at BVA. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035350 on 16 June 2020. Downloaded from 
7van den Elsen SHJ, et al. BMJ Open 2020;10:e035350. doi:10.1136/bmjopen-2019-035350
Open access
 13 Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug 
concentrations predictive of pulmonary tuberculosis outcomes. J 
Infect Dis 2013;208:1464–73.
 14 Modongo C, Pasipanodya JG, Magazi BT, et al. Artificial intelligence 
and amikacin exposures predictive of outcomes in multidrug- 
resistant tuberculosis patients. Antimicrob Agents Chemother 
2016;60:5928–32.
 15 Sekaggya- Wiltshire C, von Braun A, Lamorde M, et al. Delayed 
sputum culture conversion in tuberculosis- human immunodeficiency 
virus- coinfected patients with low isoniazid and rifampicin 
concentrations. Clin Infect Dis 2018;67:708–16.
 16 Alffenaar J- WC, Tiberi S, Verbeeck RK, et al. Therapeutic drug 
monitoring in tuberculosis: practical application for physicians. Clin 
Infect Dis 2017;64:104–5.
 17 Peloquin C. The role of therapeutic drug monitoring in mycobacterial 
infections. Microbiol Spectr 2017;5:TNMI7-00295–2016.
 18 Alkabab Y, Keller S, Dodge D, et al. Early interventions for diabetes 
related tuberculosis associate with hastened sputum microbiological 
clearance in Virginia, USA. BMC Infect Dis 2017;17:125.
 19 Deshpande D, Pasipanodya JG, Mpagama SG, et al. Levofloxacin 
pharmacokinetics/pharmacodynamics, dosing, susceptibility 
breakpoints, and artificial intelligence in the treatment of multidrug- 
resistant tuberculosis. Clin Infect Dis 2018;67:S293–302.
 20 Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose 
that suppresses drug resistance in mycobacterium tuberculosis, 
by use of an in vitro pharmacodynamic infection model and 
mathematical modeling. J Infect Dis 2004;190:1642–51.
 21 van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind- 
Vrubleuskaya N, et al. Population pharmacokinetic model and 
limited sampling strategies for personalized dosing of levofloxacin 
in tuberculosis patients. Antimicrob Agents Chemother 
2018;62:e01092–18.
 22 van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, et al. 
Limited sampling strategies using linear regression and the 
bayesian approach for therapeutic drug monitoring of moxifloxacin 
in tuberculosis patients. Antimicrob Agents Chemother 
2019;63:e00384–19.
 23 Ghimire S, Bolhuis MS, Sturkenboom MGG, et al. Incorporating 
therapeutic drug monitoring into the world health organization 
hierarchy of tuberculosis diagnostics. Eur Respir J 2016;47:1867–9.
 24 Schimke I. Quality and timeliness in medical laboratory testing. Anal 
Bioanal Chem 2009;393:1499–504.
 25 Ghimire S, van Hateren K, Vrubleuskaya N, et al. Determination of 
levofloxacin in human serum using liquid chromatography tandem 
mass spectrometry. J Appl Bioanal 2018;4:16–25.
 26 Pranger AD, Alffenaar J- WC, Wessels AMA, et al. Determination of 
moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal 
fluid by a rapid and simple liquid chromatography- tandem mass 
spectrometry method. J Anal Toxicol 2010;34:135–41.
 27 Ghimire S, Jongedijk EM, van den Elsen SHJ, et al. Cross validation 
of liquid chromatography tandem mass spectrometry method for 
quantification of levofloxacin in saliva.
 28 World Health Organization. Technical report on critical concentrations 
for drug susceptibility testing of medicines used in the treatment of 
drug- resistant tuberculosis, 2018.
 29 van Altena R, de Vries G, Haar CH, et al. Highly successful treatment 
outcome of multidrug- resistant tuberculosis in the Netherlands, 
2000-2009. Int J Tuberc Lung Dis 2015;19:406–12.
 30 Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and 
tolerability of linezolid containing regimens in treating MDR- TB 
and XDR- TB: systematic review and meta- analysis. Eur Respir J 
2012;40:1430–42.
 31 World Medical Association. World medical association declaration 
of Helsinki: ethical principles for medical research involving human 
subjects. JAMA 2013;310:2191–4.
 32 Nahid P, Dorman SE, Alipanah N, et al. Official American thoracic 
society/centers for disease control and prevention/infectious 
diseases society of America clinical practice guidelines: treatment of 
drug- susceptible tuberculosis. Clin Infect Dis 2016;63:e147–95.
 33 Lange C, Abubakar I, Alffenaar J- WC, et al. Management of 
patients with multidrug- resistant/extensively drug- resistant 
tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 
2014;44:23–63.
 34 Alffenaar J- WC, Heysell SK, Mpagama SG. Therapeutic drug 
monitoring: the need for practical guidance. Clin Infect Dis 
2019;68:1065–6.
 35 Lange C, Dheda K, Chesov D, et al. Management of drug- resistant 
tuberculosis. Lancet 2019;394:953–66.
 36 Alffenaar J- WC, Gumbo T, Dooley KE, et al. Integrating 
pharmacokinetics and pharmacodynamics in operational research to 
end tuberculosis. Clin Infect Dis 2020;70:1774–80.
 37 Migliori GB, Sotgiu G, Rosales- Klintz S, et al. ERS/ECDC statement: 
European union standards for tuberculosis care, 2017 update. Eur 
Respir J 2018;51:1702678.
 38 Nicholson T, Admay C, Shakow A, et al. Double standards in global 
health: medicine, human rights law and multidrug- resistant TB 
treatment policy. Health Hum Rights 2016;18:85–102.
 39 Ghimire S, Maharjan B, Jongedijk EM, et al. Evaluation of saliva as a 
potential alternative sampling matrix for therapeutic drug monitoring 
of levofloxacin in patients with multidrug- resistant tuberculosis. 
Antimicrob Agents Chemother 2019;63:e02379–18.
 40 Zuur MA, Bolhuis MS, Anthony R, et al. Current status and 
opportunities for therapeutic drug monitoring in the treatment of 
tuberculosis. Expert Opin Drug Metab Toxicol 2016;12:509–21.
 41 Zentner I, Modongo C, Zetola NM, et al. Urine colorimetry for 
therapeutic drug monitoring of pyrazinamide during tuberculosis 
treatment. Int J Infect Dis 2018;68:18–23.
 42 Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of 
patients with multidrug- resistant tuberculosis. Int J Tuberc Lung Dis 
2019;23:645–62.
 43 van der Burgt EPM, Sturkenboom MGG, Bolhuis MS, et al. End TB 
with precision treatment! Eur Respir J 2016;47:680–2.
 44 Figueras A. WHO report ‘review of the evidence to include TDM in 
the essential in vitro diagnostics list and prioritization of medicines to 
be monitored’, 2019.
 45 Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of 
bedaquiline- containing regimens in the treatment of MDR- and XDR- 
TB: a multicentre study. Eur Respir J 2017;49:1700387.
 46 Bolhuis MS, Tiberi S, Sotgiu G, et al. Is there still room for 
therapeutic drug monitoring of linezolid in patients with tuberculosis? 
Eur Respir J 2016;47:1288–90.
 47 Alffenaar J- WC, van Altena R, Harmelink IM, et al. Comparison of the 
pharmacokinetics of two dosage regimens of linezolid in multidrug- 
resistant and extensively drug- resistant tuberculosis patients. Clin 
Pharmacokinet 2010;49:559–65.
 48 Bolhuis MS, Akkerman OW, Sturkenboom MGG, et al. Linezolid- 
based regimens for multidrug- resistant tuberculosis (TB): a 
systematic review to establish or revise the current recommended 
dose for TB treatment. Clin Infect Dis 2018;67:S327–35.
 49 Migliori GB, Nardell E, Yedilbayev A, et al. Reducing tuberculosis 
transmission: a consensus document from the world 
health organization regional office for Europe. Eur Respir J 
2019;53:1900391.
 o
n
 June 23, 2020 at BVA. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035350 on 16 June 2020. Downloaded from 
